Scarica l'app Stockscreener
15.19
1.49%
-0.23
Precedente Chiudi:
$15.42
Aprire:
$15.42
Volume 24 ore:
799.45K
Relative Volume:
0.88
Capitalizzazione di mercato:
$948.72M
Reddito:
-
Utile/perdita netta:
$-69.71M
Rapporto P/E:
-12.73
EPS:
-1.1935
Flusso di cassa netto:
$-54.12M
1 W Prestazione:
-2.88%
1M Prestazione:
+42.50%
6M Prestazione:
+61.77%
1 anno Prestazione:
+275.99%
Intervallo 1D:
$14.20
$15.55
Intervallo di 1 settimana:
$14.20
$15.86
Portata 52W:
$3.76
$17.25
Design Therapeutics Inc Stock (DSGN) Company Profile
Nome
Design Therapeutics Inc
Settore
Industria
Telefono
858-293-4900
Indirizzo
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
15.19 | 948.72M | 0 | -69.71M | -54.12M | -1.1935 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Iniziato | Jefferies | Buy |
| 2026-01-07 | Iniziato | Oppenheimer | Outperform |
| 2025-12-03 | Iniziato | Craig Hallum | Buy |
| 2025-12-03 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-11-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-05-04 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-06-10 | Iniziato | Wedbush | Outperform |
| 2022-05-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-01-19 | Iniziato | Goldman | Sell |
| 2021-04-20 | Iniziato | Goldman | Neutral |
| 2021-04-20 | Iniziato | Piper Sandler | Overweight |
| 2021-04-20 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Design Therapeutics Inc Borsa (DSGN) Ultime notizie
Myotonic Dystrophy Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Design Therapeutics, Enzerna, Juvena Therapeutics, Dyne Therapeutics, Avidity Bioscien - Barchart.com
Myotonic Dystrophy Market Expected to Experience Accelerated - openPR.com
If You Invested $1,000 in Design Therapeutics, Inc. (DSGN) - Stock Titan
Price to sales forward of Design Therapeutics, Inc. – NASDAQ:DSGN - TradingView
Price to earnings forward of Design Therapeutics, Inc. – NASDAQ:DSGN - TradingView
DESIGN THERAPEUTICS INC (DSGN) Stock Chart - ChartMill
Cantor Fitzgerald reiterates Design Therapeutics stock rating - Investing.com
Design Therapeutics stock rises on Phase 1 trial dosing start - Investing.com
Design Therapeutics stock rises on Phase 1 trial dosing start By Investing.com - Investing.com Nigeria
Design Therapeutics begins dosing DM1 drug in phase 1 trial By Investing.com - Investing.com South Africa
Design Therapeutics begins dosing DM1 drug in phase 1 trial - Investing.com
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1 - The Manila Times
Design Therapeutics begins DM1 trial for DT-818, aims at genetic cause - Stock Titan
Myotonic Dystrophy Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma - Barchart.com
Design Therapeutics spikes as RBC upgrades on an eventful 2026 - MSN
Design Therapeutics, Inc.(NasdaqGS:DSGN) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Design Therapeutics, Inc.(NasdaqGS: DSGN) added to Russell 2500 Growth Benchmark - marketscreener.com
Design Therapeutics, Inc.(NasdaqGS: DSGN) dropped from Russell 2000 Value Benchmark - marketscreener.com
Design Therapeutics, Inc.(NasdaqGS:DSGN) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Design Therapeutics, Inc.(NasdaqGS:DSGN) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Design Therapeutics, Inc.(NasdaqGS: DSGN) added to Russell 2000 Growth Benchmark - marketscreener.com
Design Therapeutics, Inc.(NasdaqGS: DSGN) added to Russell 3000E Growth Benchmark - marketscreener.com
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely - Sahm
Design Therapeutics, Inc. Actuals & Estimates (NASDAQ:DSGN) - TradingView
Design Therapeutics, Inc. Actuals & Estimates (BOATS:DSGN) - TradingView
DSGN Forecast — Price Target — Prediction for 2027 - TradingView
DSGN News | DESIGN THERAPEUTICS INC (NASDAQ:DSGN) - ChartMill
Design Therapeutics, Inc. (DSGN) is up 6.92% in one week: What you should know - MSN
Design Therapeutics Inc (DSGN) Institutional Confidence - TradingKey
Design Therapeutics stock wobbles after rare genetic disease data - MSN
Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts - Seeking Alpha
Design Therapeutics Inc (DSGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
DSGN Q1 2026 Earnings: Narrowed Loss Beats Expectations as Pipeline AdvancesRevenue Warning Signal - dars.gov.et
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting - Business Wire
Design Therapeutics Inc (DSGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Design Therapeutics Inc (DSGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Design Therapeutics Inc (DSGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Design Therapeutics Inc (DSGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Design Therapeutics Inc (DSGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Design Therapeutics Inc (DSGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Design Therapeutics Inc (DSGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Design Therapeutics (DSGN) Gains 2.28% – Approaching Key Resistance at $11.78Weekly Profile - newsline.com
Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Lexeo Therapeutics Announces Regulatory Update and - GlobeNewswire
DSGN Q1 2026 Earnings: EPS Beat as Net Loss NarrowsEarnings Expansion Phase - newsline.com
Design Therapeutics Stockholders Approve Director and Auditor at Meeting - TipRanks
Design Therapeutics (DSGN) grants George Simeon 30,000 stock options at $10.55 - Stock Titan
[Form 4] Design Therapeutics, Inc. Insider Trading Activity - Stock Titan
Design Therapeutics (DSGN) director awarded 30,000 options at $10.55 strike - Stock Titan
Director at Design Therapeutics (DSGN) awarded options on 30,000 shares - Stock Titan
Design Therapeutics (DSGN) grants director David Shapiro 30,000 options - Stock Titan
Design Therapeutics Inc Azioni (DSGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):